Alpha-Stim® Results at a Glance
Physician Post-Marketing Survey on 500 Alpha-Stim® Patients
Condition |
N |
Worse |
No Change |
Slight <24% |
Fair
25-49% |
Moderate 50-74% |
Marked 75-99% |
Complete 100% |
Significant >25% |
Pain |
286 |
.35% |
1.75% |
6.99% |
16.78% |
26.92% |
37.76% |
9.44% |
90.91% |
Anxiety |
349 |
0% |
2.29% |
4.01% |
11.17% |
25.5% |
51.86% |
5.16% |
93.7% |
Depression |
184 |
0% |
4.35% |
5.89% |
16.85% |
20.65% |
44.57% |
7.61% |
89.67% |
Stress |
259 |
0% |
2.32% |
4.63% |
14.29% |
27.03% |
47.88% |
3.86% |
93.05% |
Insomnia |
135 |
0% |
11.85% |
8.89% |
12.59% |
25.19% |
33.33% |
8.15% |
79.26% |
Headache |
151 |
.66% |
5.3% |
3.97% |
16.56% |
21.19% |
41.72% |
10.6% |
90.07% |
Muscle Tension |
259 |
.77% |
2.32% |
2.32% |
16.22% |
29.34% |
42.86% |
6.18% |
94.59% |
Results of using Alpha-Stim® technology as reported by healthcare practitioners. Total N = 500 patients with multiple symptoms. For additional information see the book: Kirsch, Daniel L. The Science Behind Cranial Electrotherapy Stimulation. Medical Scope Publishing Corporation, Edmonton, Alberta, Canada, 2002.
Peer-Reviewed Outcomes on 2,500 Alpha-Stim® Patients Self-Reports
Condition |
N |
Slight
<24% |
Fair
25-49% |
Moderate
50-74% |
Marked
75-100% |
Significant
>25% |
| Pain (all cases) |
1949 |
6.98% |
31.97% |
38.02% |
23.04% |
93.02% |
| Back Pain |
403 |
4.69% |
27.05% |
38.96% |
29.03% |
95.04% |
| Cervical Pain |
265 |
6.79% |
26.04% |
47.17% |
20% |
93.21% |
| Hip/Leg/Foot Pain |
160 |
3.75% |
26.88% |
33.13% |
36.25% |
96.25% |
| Shoulder/Arm/Hand Pain |
150 |
8.67% |
27.33% |
42% |
22% |
91.33% |
| Carpal Tunnel |
25 |
0% |
20% |
68% |
12% |
100% |
| Arthritis Pain |
188 |
5.85% |
27.13% |
46.81% |
20.21% |
94.15% |
| TMJ Pain |
158 |
10.76% |
37.97% |
37.97% |
13.29% |
89.24% |
| Myofascial Pain |
62 |
9.68% |
29.03% |
29.03% |
32.26% |
90.32% |
| RSD |
55 |
18.18% |
29.09% |
34.55% |
18.18% |
81.82% |
| Fibromyalgia (alone) |
142 |
9.15% |
37%.32% |
36.62% |
16.9% |
90.85% |
| Fibromyalgia (with other) |
363 |
9.09% |
36.09% |
41.87% |
12.95% |
90.91% |
| Migraine |
118 |
1.69% |
41.53% |
25.42% |
31.36% |
98.31% |
| Headaches (all other) |
112 |
17.86% |
26.79% |
21.43% |
33.93% |
82.14% |
| Psychological (all cases) |
723 |
8.44% |
24.2% |
32.78% |
34.58% |
91.56% |
| Anxiety (alone) |
128 |
10.16% |
22.66% |
32.81% |
34.38% |
89.84% |
| Anxiety (with other) |
370 |
8.92% |
22.97% |
32.97% |
35.14% |
91.08% |
| Anxiety/Depression |
58 |
5.17% |
32.76% |
32.76% |
29.31% |
94.83% |
| Depression (alone) |
53 |
13.21% |
20.75% |
43.4% |
22.64% |
86.79 |
| Depression (with other) |
265 |
10.94% |
23.02% |
35.09% |
30.94% |
89.06% |
| Stress |
123 |
4.88% |
24.39% |
31.71% |
39.02% |
95.12% |
| Chronic Fatigue |
50 |
6% |
60% |
20% |
14% |
94% |
| Insomnia |
163 |
6.13% |
28.83% |
28.83% |
36.2% |
93.87% |
Results of using Alpha-Stim® technology at least 3 weeks from consecutive warranty cards. Total N = 2,500 patients with multiple symptoms. For additional information see: Smith, Ray B. Is microcurrent stimulation effective in pain management? An additional perspective. American Journal of Pain Management, 11(2):62-66, 2001.
